<?xml version="1.0" encoding="UTF-8"?>
<ref id="B46-pharmaceutics-10-00039">
 <label>46.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Walker</surname>
    <given-names>D.K.</given-names>
   </name>
   <name>
    <surname>Bowers</surname>
    <given-names>S.J.</given-names>
   </name>
   <name>
    <surname>Mitchell</surname>
    <given-names>R.J.</given-names>
   </name>
   <name>
    <surname>Potchoiba</surname>
    <given-names>M.J.</given-names>
   </name>
   <name>
    <surname>Schroeder</surname>
    <given-names>C.M.</given-names>
   </name>
   <name>
    <surname>Small</surname>
    <given-names>H.F.</given-names>
   </name>
  </person-group>
  <article-title>Preclinical assessment of the distribution of maraviroc to potential human immunodeficiency virus (HIV) sanctuary sites in the central nervous system (CNS) and gut-associated lymphoid tissue (GALT)</article-title>
  <source>Xenobiotica</source>
  <year>2008</year>
  <volume>38</volume>
  <fpage>1330</fpage>
  <lpage>1339</lpage>
  <pub-id pub-id-type="doi">10.1080/00498250802447409</pub-id>
  <?supplied-pmid 18853388?>
  <pub-id pub-id-type="pmid">18853388</pub-id>
 </element-citation>
</ref>
